The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 01, 2022
Filed:
Aug. 24, 2017
Serum Institute of India Private Limited, Pune Maharashtra, IN;
The United States of America, As Represented BY the Secretary, Department of Health and Human Services, Bethesda, MD (US);
Rajeev Mhalasakant Dhere, Pune Maharashtra, IN;
Sambhaji Shankar Pisal, Pune Maharashtra, IN;
Jagdish Kamalaji Zade, Pune Maharashtra, IN;
Rajendra Narayan Sabale, Pune Maharashtra, IN;
Ravindra Bapurao Kadam, Pune Maharashtra, IN;
Abhijeet Sanjeev Kamble, Pune Maharashtra, IN;
Baoming Jiang, Bethesda, MD (US);
Roger Glass, Bethesda, MD (US);
Serum Institute of India Private Limited, Pune Maharashtra, IN;
The United States of America, as Represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US);
Abstract
Stable, immunogenic combination vaccine(s) comprising a mixture of antigens for prevention and prophylaxis of infections caused by Rotavirus, Poliomyelitis virus, Haemophilus influenzae, Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis and Hepatitis B virus. A multivalent combination vaccine comprises i) significantly dose-reduced Salk-IPV or Sabin-IPV (IPV) antigens prepared by methods of formaldehyde inactivation and alum hydroxide adsorption resulting in maximum D-antigen recovery; ii) Injectable heat inactivated Rotavirus antigen(s) providing broad cross-protective immunity among human rotavirus strains; iii) Hib PRP-carrier protein conjugate having improved stability and immunogenicity; iv) whole cell pertussis antigen with improved immunogenicity and stability; and v) Homogenous fractions of Diphtheria and Tetanus toxoids. Such stable and immunogenic vaccine compositions are made by i) individually adsorbing dose reduced IPV, IRV antigens on alum hydroxide and keeping other antigen(s) unadsorbed or adsorbed on alum phosphate, alum hydroxide, or a combination thereof; and ii) using an order of addition of antigens during blending.